| CAS ID: | 224785-90-4 |
| Molecular Formula: | C23H32N6O4S |
| Molecular Weight: | 488.6 g/mol |
| Monoisotopic Mass: | 488.2206 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | VARDENAFIL DIHYDROCHLORIDE | LEVITRA | STAXYN | VARDENAFIL HYDROCHLORIDE | VARDENAFIL |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30) | See All |
| InChI Key: | SECKRCOLJRRGGV-UHFFFAOYSA-N | |
| Smiles: | CCCc1nc(C)c2C(=O)N=C(Nn12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC)CC4 | See All |
| Molfile: | Download |
Reference Record 1
Reference Record 2
| PubMed ID | 28196856 | Target ID | T0431 |
| Uniprot ID | cGMP-specific 3',5'-cyclic phosphodiesterase | Name | cGMP-specific 3',5'-cyclic phosphodiesterase |
| Model | vitro,mice | Fibrosis Disease | Cystic fibrosis |
| Process I | attenue inflammation | ||
| Process II | macrophages polarization | ||
| Process III | |||
| Mechanism | Targeting PDE5- and CFTR-dependent mechanisms | ||
Trial Record 1
| ClinicalTrial ID | NCT01002534 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Terminated |
| First Received | October 27, 2009 | Last Verified | February 25, 2019 |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | ||
Trial Record 2
| ClinicalTrial ID | NCT02344823 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | January 26, 2015 | Last Verified | September 25, 2015 |
| Sponsor | Medical University of Vienna | ||
| PubChem: | 110634 |
| ChEMBL: | CHEMBL1520 |